graves ophthalmopathy
Showing NaN - NaN of 1
Graves Ophthalmopathy Trial in Newcastle upon Tyne (Otelixizumab - low dose, Otelixizumab - medium low dose, Otelixizumab -
Terminated
- Graves Ophthalmopathy
- Otelixizumab - low dose
- +5 more
-
Newcastle upon Tyne, United KingdomGSK Investigational Site
Oct 8, 2020